EyePoint Pharmaceuticals EYPT
$ 8.94
7.07%
Quarterly report 2024-Q3
added 11-07-2024
EyePoint Pharmaceuticals ROE Ratio 2011-2024 | EYPT
Annual ROE Ratio EyePoint Pharmaceuticals
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-26.58 | -106.11 | -31.68 | -244.83 | -681.79 | -454.96 | -138.61 | -103.19 | 27.16 | -89.49 | -154.55 | -182.13 | -23.05 |
All numbers in USD currency
Indicator range from annual reports
Maximum | Minimum | Average |
---|---|---|
27.16 | -681.79 | -169.98 |
Quarterly ROE Ratio EyePoint Pharmaceuticals
2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
-69.95 | -96.56 | -88.54 | -102.05 | -94.04 | -66.84 | -38.9 | -56.9 | -61.4 | -57.94 | -37.98 | -58.48 | -60.98 | -121.46 | -161.4 | -286.37 | -453.71 | -521.89 | -681.79 | -587.63 | -487.81 | -441.26 | -298.34 | -325.91 | -304.35 | -271.24 | -249.69 | -191.77 | -175.29 | -117.37 | -100.47 | -135.97 | -112.19 | -147.69 | -124.32 | -100.99 | -17.34 | 5.98 | 170.0 | 154.73 | 71.39 | 38.38 | -147.31 | -138.3 | -128.19 | -101.68 | -72.5 | -151.75 | -142.85 | -170.37 | -158.14 | -6.89 | -46.64 | -6.48 |
All numbers in USD currency
Indicator range from quarterly reporting
Maximum | Minimum | Average |
---|---|---|
170.0 | -681.79 | -150.69 |